Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho ("s-KL") RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis ("ALS") and multiple sclerosis.
The Canadian patent expands the company's intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines noted that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. This news is significant because it strengthens the company's position in the emerging field of gene therapy for neurodegenerative diseases, which affect millions of people worldwide.
According to the press release, the company views this patent as a key step in building a multi-asset platform. Greenland Mines operates two divisions: Mining, focused on exploration and development of projects in Greenland, and Biotech, including Klotho's KLTO-202 primary indication for ALS. The company's strategy centers on building exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure. The patent news underscores the potential of its biotech division to create value for shareholders.
For more details, the full press release can be viewed at https://ibn.fm/x2pHA. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
